Last edition
News about "US FDA "
US FDA Expands OTC Access to Naloxone Nasal Spray for Opioid Overdose
US FDA expands Over-the-Counter (OTC) access to naloxone nasal spray for opioid overdose, supporting efforts to prevent overdose deaths and strengthen addiction recovery initiatives under the US government’s public health strategy.
US FDA | 18/06/2026 | By News Bureau
Rznomics Secures US FDA RMAT Designation for Liver Cancer Gene Therapy Candidate RZ-001
The FDA has granted Regenerative Medicine Advanced Therapy designation to RZ-001, an RNA-based gene therapeutic for hepatocellular carcinoma, accelerating its clinical development and regulatory review pathway.
US FDA | 11/05/2026 | By News Bureau
US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib
Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.
US FDA | 04/05/2026 | By News Bureau | 277
AstraZeneca Wins US Approval for Self-Administered Saphnelo Pen for Lupus Treatment
AstraZeneca launches a self-injectable version of Saphnelo, offering lupus patients a more convenient treatment option with proven efficacy and safety.
US FDA | 28/04/2026 | By News Bureau | 157
Alembic Pharmaceuticals Secures US FDA Nod for Fingolimod Capsules
Alembic Pharmaceuticals receives US FDA approval for fingolimod capsules, expanding access to a key multiple sclerosis treatment in the US market.
US FDA | 27/04/2026 | By News Bureau | 107
US Food and Drug Administration Extends Review Timeline for Sarclisa Subcutaneous Formulation
FDA extends review timeline for Sanofi’s Sarclisa subcutaneous formulation, a potential first-in-class on-body injector therapy for multiple myeloma patients.
US FDA | 23/04/2026 | By News Bureau | 157
Roche Secures FDA Review for Lupus Drug Gazyva
Roche’s Gazyva moves closer to approval for systemic lupus erythematosus after FDA accepts application backed by Phase III trial results showing improved disease control and remission rates.
US FDA | 22/04/2026 | By News Bureau
US Food and Drug Administration Urges Compliance on Clinical Trial Reporting to Address Data Gaps
The US Food and Drug Administration has issued reminders to over 2,200 companies and researchers to submit clinical trial results, aiming to reduce reporting gaps and improve transparency in drug development.
US FDA | 15/04/2026 | By News Bureau | 124
Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer
The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.
US FDA | 08/04/2026 | By News Bureau | 122
Denali Therapeutics Wins FDA Approval for AVLAYAH in Hunter Syndrome
US FDA approves Denali Therapeutics’ AVLAYAH for Hunter syndrome (MPS II), the first new treatment in nearly 20 years and a novel biotherapeutic designed to cross the blood-brain barrier.
US FDA | 26/03/2026 | By News Bureau | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy